Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Medical Officer | February 22, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date February 22, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,111 |
Reported balance
After 2024-02-22 transaction · row 1
1 source rowRow 1 · 2024-02-22 · Sale · Disposed 14,568 · Balance 250,111 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 91 | $44.97 | $4,092.27 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,050 | $44.10 | $90,405.00 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,409 | $43.46 | $191,615.14 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,918 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.83 to $43.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 950 | $41.82 | $39,729.00 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,327 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.41 to $42.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-21-065833 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,129 Underlying: Common Stock · 5,000 shares Expires 2029-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 465 | $36.80 | $17,112.14 |
DisclosureSEC source: 0001209191-21-065833 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,535 | $35.75 | $162,142.58 |
DisclosureSEC source: 0001209191-21-065833 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,742 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.21 to $35.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $5.18 | $25,875.00 |
DisclosureSEC source: 0001209191-21-065833 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 23:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-21-063007 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,129 Underlying: Common Stock · 5,000 shares Expires 2029-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 23:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $36.47 | $182,330.50 |
DisclosureSEC source: 0001209191-21-063007 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 23:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $5.18 | $25,875.00 |
DisclosureSEC source: 0001209191-21-063007 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,000 | $39.65 | $158,596.00 |
DisclosureSEC source: 0001209191-21-061384 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 22:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $34.56 | $172,780.50 |
DisclosureSEC source: 0001209191-21-059979 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-21-058071 · doc4.xml · derivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,833 Underlying: Common Stock · 5,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $0.86 | $4,275.00 |
DisclosureSEC source: 0001209191-21-058071 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 19:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 720 | $50.36 | $36,259.20 |
DisclosureSEC source: 0001209191-21-056602 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.282 to $50.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 19:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,280 | $49.58 | $212,202.40 |
DisclosureSEC source: 0001209191-21-056602 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,997 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-054577 · doc4.xml · derivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,107 | $50.43 | $106,250.32 |
DisclosureSEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.295 to $50.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,005 | $49.40 | $49,642.38 |
DisclosureSEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,384 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.28 to $49.775 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,888 | $48.72 | $91,986.19 |
DisclosureSEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,389 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.16 to $49.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-052790 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $42.23 | $211,160.50 |
DisclosureSEC source: 0001209191-21-052790 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:52 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-21-052790 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 00:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-21-050065 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,129 Underlying: Common Stock · 5,000 shares Expires 2029-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 00:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $34.92 | $174,604.00 |
DisclosureSEC source: 0001209191-21-050065 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.61 to $35.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 00:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $5.18 | $25,875.00 |
DisclosureSEC source: 0001209191-21-050065 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,630 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-21-047978 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,982 Underlying: Common Stock · 4,630 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,630 | $37.44 | $173,347.20 |
DisclosureSEC source: 0001209191-21-047978 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.12 to $37.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 4,630 | $1.58 | $7,292.25 |
DisclosureSEC source: 0001209191-21-047978 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-21-046012 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,129 Underlying: Common Stock · 5,000 shares Expires 2029-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,495 | $40.91 | $61,158.81 |
DisclosureSEC source: 0001209191-21-046012 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.60 to $41.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,505 | $40.16 | $140,772.02 |
DisclosureSEC source: 0001209191-21-046012 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,772 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.60 to $40.57 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $5.18 | $25,875.00 |
DisclosureSEC source: 0001209191-21-046012 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 21:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-21-041516 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,129 Underlying: Common Stock · 5,000 shares Expires 2029-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 21:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $43.67 | $218,346.00 |
DisclosureSEC source: 0001209191-21-041516 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.19 to $43.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 21:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $5.18 | $25,875.00 |
DisclosureSEC source: 0001209191-21-041516 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 23:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-21-037937 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,833 Underlying: Common Stock · 10,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 23:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 300 | $42.18 | $12,654.99 |
DisclosureSEC source: 0001209191-21-037937 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 23:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,700 | $41.47 | $402,219.23 |
DisclosureSEC source: 0001209191-21-037937 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,577 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $42.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 23:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,000 | $0.86 | $8,550.00 |
DisclosureSEC source: 0001209191-21-037937 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $67.38 | $0.00 |
DisclosureSEC source: 0001209191-21-011921 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2031-02-15 F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-21-011921 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,833 Underlying: Common Stock · 10,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011921 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,277 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,000 | $0.86 | $8,550.00 |
DisclosureSEC source: 0001209191-21-011921 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-21-011384 · doc4.xml · derivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,833 Underlying: Common Stock · 10,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,000 | $0.86 | $8,550.00 |
DisclosureSEC source: 0001209191-21-011384 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-20-060970 · doc4.xml · derivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,833 Underlying: Common Stock · 7,500 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:03 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,500 | $0.86 | $6,412.50 |
DisclosureSEC source: 0001209191-20-060970 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.